IsoRay nets $527K for brachytherapy development
Brachytherapy technology developer IsoRay has received a $526,910 award under the Qualifying Therapeutic Discovery Program (QTDP), which is part of the Patient Protection and Affordable Care Act of 2010.
The award will be directed to Cesium-131 (Cs-131) brachytherapy seed usage in three areas, according to Richland, Wash.-based IsoRay. A portion of the funds will further develop use of the seed in three areas:
The award will be directed to Cesium-131 (Cs-131) brachytherapy seed usage in three areas, according to Richland, Wash.-based IsoRay. A portion of the funds will further develop use of the seed in three areas:
- Internal radiation therapy in conjunction with lumpectomy surgery for early stage breast cancer in accelerated partial breast irradiation;
- Lung cancer and sub-lobar resection in Stage I non-small cell lung cancer; and
- Manufacture of IsoRay's GliaSite radiation therapy balloon catheter system, which delivers internal radiation therapy for operable brain cancer.